戻る Agenda
Session 10: Regional Updates
Session Chair(s)
E. Stewart Geary, MD
Senior Vice President
Eisai Co., Ltd., Japan
This session focuses on countries or regions where pharmacovigilance regulations are in transition or where recent updates can present compliance issues for clinical trial Sponsors or Marketing Authorization Holders. The Eurasian Economic Union (EAEU), which includes Russia and a number of states in northern Eurasia, now has a Good Pharmacovigilance Practice (GVP) guideline and requirement for a QPPV, which will be described and explained. In Japan the “Three Officer System” is undergoing revisions in the face of a number of compliance issues that have surfaced in that country and the countries Good Postmarketing Survey Practice (GPSP) is also being modified. An update on the implementation of Vanessa’s Law (the Protecting Canadians from Unsafe Drugs Act), one of the most significant changes to the Canadian Food and Drug Act in 50 years, and its implications for pharmacovigilance in that country will also be presented.
Speaker(s)
The Evolving Situation in Japan: The “Three Officer System” and GPSP
Shinobu Uzu, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Senior Executive Director
Modernization Efforts in Canada: The Regulatory Review of Drugs and Devices and Vanessa’s Law
Melissa Hunt, MSc
Health Canada, Canada
Director
CRO Perspectives on New PV Requirements in the EAEU
Simon Johns
IQVIA, United Kingdom
Director, Medical Information and Marketed Product Safety
What New EAEU PV Obligations Mean for a Global Company with a Focus on Russia
Tatyana Prokhorova
Pfizer LLC, Russia EAEU/Ukraine QPPV, Russian Federation
Cluster Safety Lead